Alchemab Therapeutics expands leadership team, appointing Dr Ben Porter-Brown as CMO to propel the clinical advancement of its pipeline

Cambridge, UK – Clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as Chief Medical Officer (CMO) to accelerate the clinical development of the company’s pipeline of highly novel antibody therapeutics. Alchemab is discovering and developing first-in-class drugs through its Resiliome™ platform, which combines the world’s largest immune database derived […]